Du Yikuan, Huo Yuying, Yang Yujia, Lin Peiqi, Liu Wuzheng, Wang Ziqin, Zeng Wenqi, Li Jiahui, Liang Zhonghan, Yuan Chenyue, Zhu Jinfeng, Luo Ziyi, Liu Yi, Ma Chunling, Yang Chun
Central Laboratory, The Tenth Affiliated Hospital of Southern Medical University, Dongguan, 523059, China.
Dongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, The First Dongguan Affiliated Hospital, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, 523808, China.
Cell Commun Signal. 2025 Jan 11;23(1):20. doi: 10.1186/s12964-024-02025-7.
The prevalence of obesity and osteoporosis (OP) represents a significant public health concern on a global scale. A substantial body of evidence indicates that there is a complex relationship between obesity and OP, with a correlation between the occurrence of OP and obesity. In recent years, sirtuins have emerged as a prominent area of interest in the fields of aging and endocrine metabolism. Among the various research avenues exploring the potential of sirtuins, the effects of these proteins on obesity and OP have garnered significant attention from numerous researchers. Sirtuins regulate energy balance and lipid balance, which in turn inhibit the process of adipogenesis. Additionally, sirtuins regulate the balance between osteogenic and osteoblastic activity, which protects against the development of OP. However, no study has yet provided a comprehensive discussion of the relationship between the three: sirtuins, obesity, and OP. This paper will therefore describe the relationship between sirtuins and obesity, the relationship between sirtuins and OP, and a discussion focusing on the possibility of treating OP caused by obesity by targeting sirtuins. This will be based on the common influences on the occurrence of obesity and OP (such as mesenchymal stem cells, gut microbiota, and insulin). Finally, the potential of SIRT1, an important member of sirtuins, in polyphenolic natural products for the treatment of obesity and OP will be presented. This will contribute to a better understanding of the interactions between sirtuins and obesity and bone, which will facilitate the development of new therapeutic strategies for obesity and OP in the future.
肥胖症和骨质疏松症(OP)的患病率是全球范围内重大的公共卫生问题。大量证据表明,肥胖与OP之间存在复杂关系,OP的发生与肥胖之间存在相关性。近年来,沉默调节蛋白已成为衰老和内分泌代谢领域的一个重要研究热点。在探索沉默调节蛋白潜力的各种研究途径中,这些蛋白质对肥胖和OP的影响引起了众多研究人员的极大关注。沉默调节蛋白调节能量平衡和脂质平衡,进而抑制脂肪生成过程。此外,沉默调节蛋白调节成骨与破骨细胞活性之间的平衡,从而预防OP的发生。然而,尚无研究全面探讨沉默调节蛋白、肥胖和OP这三者之间的关系。因此,本文将描述沉默调节蛋白与肥胖之间的关系、沉默调节蛋白与OP之间的关系,并重点讨论通过靶向沉默调节蛋白治疗肥胖所致OP的可能性。这将基于对肥胖和OP发生的共同影响因素(如间充质干细胞、肠道微生物群和胰岛素)展开。最后,将介绍沉默调节蛋白的重要成员SIRT1在多酚类天然产物治疗肥胖和OP方面的潜力。这将有助于更好地理解沉默调节蛋白与肥胖和骨骼之间的相互作用,从而为未来肥胖和OP新治疗策略的开发提供便利。